Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy
Launched by NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE (NINDS) · Nov 3, 1999
Current as of December 10, 2023
The purpose of this protocol is to study the effects of transcranial magnetic stimulation (TMS) at 1 Hz on the excitability of the seizure focus in patients with poorly controlled epilepsy refractory to pharmacological treatments. 1 Hz TMS is a rate proven to induce long term depression in animal models and reported to decrease the excitability of both human and animal cerebral cortex.
- Age 5 to 60 at entry to protocol.
- History of partial or Complex Partial Epilepsy for two or more years.
- Patients should be on a stable anti-convulsant regimen defined as unchanged medicines and dose modifications lower than 20% in the last month. Blood levels of anti-convulsants will be measured at the beginning of the study, prior to stimulation and after the study to assure that the type and dose of medication will remain constant.
- Seizures not completely responsive to medical treatment (1 or more seizures per week for at least 6 months) and patients have failed at least two anti-convulsant regimens in the past.
- The patients have a localized seizure focus.
- Epilepsy refractory to medical treatments.
- No pregnant women (will be tested with urine pregnancy test).
- No severe coronary disease.
- No metal anywhere in the cranium except the mouth.
- No intracardiac lines.
- No increased intracranial pressure as expressed by the presence of papilledema.
- No cardiac pacemakers.
- Must not be taking neuroleptic or antidepressant medications.
- No progressive neurologic disease.
The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Bethesda, Maryland, United States
All reviews come from applied patients